CD274 and gastric cancer: Based on these results, nivolumab plus chemotherapy was approved in the USA, Japan, Korea, China, and Taiwan for patients with advanced gastric cancer regardless of their PD-L1 CPS, and in Europe for patients with CPS ≥ 5.